Pulmatrix, Inc. (PULM) stock
Close on Nov 12, 2026Market cap $4.75MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $4.75M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.86
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$4.01M
- EPS, diluted
- -$1.10
- Book value per share
- $0.70
- Diluted shares
- 4M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.31
- Open
- $1.27
- Day's range
- $1.22 – $1.34
- Volume
- 9,831
- Average volume (20 days)
- 39,103
- Beta (5 years)
- 0.41
- 52-week range
- $1.06 – $4.98
- RSI (14 days)
- 41.0
- Volatility (1 year)
- 89.0%
- Relative volume
- 0.35×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PULM | S&P 500 | Difference | PULM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.1% | -2.7% | −6.4 pts | ||
| 3 months | -18.8% | -1.7% | −17.0 pts | ||
| Year to date | -41.7% | +11.9% | −53.6 pts | ||
| 1 year | -73.4% | +12.0% | −85.3 pts | ||
| 3 years | -25.3% | +78.2% | −103.5 pts | -9.3% | +21.2% |
| 5 years | -92.2% | +73.2% | −165.4 pts | -39.9% | +11.6% |
| 10 years | -99.3% | +309.6% | −408.9 pts | -39.0% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pulmatrix filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
About Pulmatrix
Pharmaceutical Preparations
Pulmatrix, Inc. is a biopharmaceutical company focused on developing inhaled therapeutic products to prevent and treat central nervous system disorders and serious respiratory diseases. Using its proprietary dry powder delivery technology platform, iSPERSE, the company designs small, dense, and dispersible particles that deliver small or large molecule drugs into the airways without reliance on conventional lactose blends. Its proprietary clinical product pipeline includes PUR3100 for acute migraine, PUR1800 for acute exacerbations of chronic obstructive pulmonary disease, and PUR1900 for allergic bronchopulmonary aspergillosis in patients with asthma or cystic fibrosis.
Company profile, executives and historyPulmatrix stock: common questions
What is Pulmatrix's stock price?
PULM closed at $1.30 on Nov 12, 2026, down 0.77% on the day. Over the past 52 weeks it traded between $1.06 and $4.98.
What is Pulmatrix's market cap?
Pulmatrix was worth $4.75M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PULM's P/E ratio?
Pulmatrix lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.10), so it has no meaningful P/E ratio.
Does Pulmatrix pay a dividend?
No. Pulmatrix has not paid a cash dividend over the last twelve months.
When does Pulmatrix report earnings next?
Pulmatrix's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has PULM stock performed over the past year?
Including dividends, PULM returned -73.4% over the past year, against +12.0% for the S&P 500.
How many PULM shares are sold short?
0M shares were sold short at the latest FINRA report, 1.22% of the float, or 1.3 days of average trading volume.
Who are Pulmatrix's competitors?
Companies most similar to Pulmatrix by business, industry and size include PRAX, PTN, ALMS, TVRD, RANI.
See a number that looks wrong?